Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 07/31/20
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common StockGlobeNewsWire • 07/29/20
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19GlobeNewsWire • 07/23/20
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19GlobeNewsWire • 07/21/20
All You Need to Know About Arcturus Therapeutics (ARCT) Rating Upgrade to BuyZacks Investment Research • 07/13/20
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory BoardGlobeNewsWire • 07/01/20
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual ConferenceGlobeNewsWire • 06/11/20
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) DeficiencyGlobeNewsWire • 06/05/20
After Plummeting Over 30%, Are Arcturus Therapeutics Shares Still a Good Buy?The Motley Fool • 06/04/20
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus TherapeuticsGlobeNewsWire • 05/21/20
Arcturus Therapeutics' (ARCT) CEO Joseph Payne on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)GlobeNewsWire • 05/08/20
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 VaccineGlobeNewsWire • 05/04/20
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common StockGlobeNewsWire • 04/16/20
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase DeficiencyGlobeNewsWire • 04/13/20
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 VaccineGlobeNewsWire • 04/09/20
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation SystemGlobeNewsWire • 03/27/20